Generic Medicine Info
Indications and Dosage
Adult: 100 mg as single dose; may repeat if necessary 2-3 weeks after initial treatment.
Child: >2 years Same as adult dose.

Ascariasis, Hookworm infections, Trichuriasis
Adult: 100 mg bid for 3 consecutive days or 500 mg as single dose.
Child: >2 years Same as adult dose.
May be taken with or without food.
Hypersensitivity. Pregnancy.
Special Precautions
Prolonged uses. Hepatic impairment. Lactation. Children < 2 years.
Adverse Reactions
Significant: Bone marrow suppression e.g. agranulocytosis, neutropenia.
Gastrointestinal disorders: Diarrhoea, flatulence, abdominal pain, anorexia.
Hepatobiliary disorders: Hepatitis, abnormal liver tests.
Nervous system disorder: Convulsion, headache, dizziness.
Skin and subcutaneous tissue disorders: Exanthema, angioedema, urticaria, alopecia, rash.
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome.
Monitoring Parameters
Monitor blood count on higher doses and prolonged duration. Periodic assessment of haematologic, hepatic and renal function. Check for helminth ova in faeces within 3-4 weeks following initial therapy.
Symptoms: Abdominal cramps, nausea, vomiting, diarrhoea; rarely, alopecia, reversible liver function abnormalities, hepatitis, agranulocytosis, neutropenia, glomerulonephritis. Management: Administration of activated charcoal may be given.
Drug Interactions
Increased plasma concentration with cimetidine. Decreased serum concentration with carbamazepine, fosphenytoin, phenytoin.
Potentially Fatal: Co-administration of metronidazole may increase risk of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Food Interaction
Increased serum levels with food.
Description: Mebendazole, a benzimidazole carbamate derivative, is an anthelmintic with activity against most nematodes and some other worms by interfering the formation of helminth microtubules and causes ultrastructural degenerative changes in the intestine. It selectively and irreversibly blocks glucose uptake and disrupts digestive and reproductive functions resulting to immobilization, inhibition of egg production and death of the helminth.
Absorption: Poorly absorbed from the GI tract. Increased serum level with food. Time to peak plasma concentration: 1.5-7.25 hours.
Distribution: Crosses blood-brain barrier and enters breast milk. Volume of distribution: 1-2 L/kg. Plasma protein binding: 90-95%
Metabolism: Extensively metabolised in the liver via first pass effect. Primary metabolite: 2-amine hydrolysed metabolite.
Excretion: Mainly via faeces; urine (<2%). Elimination half-life: 3-6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Mebendazole, CID=4030, (accessed on Jan. 21, 2020)

Store between 20-25°C. Protect from light.
MIMS Class
ATC Classification
P02CA01 - mebendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal.
Anon. Mebendazole. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/07/2014.

Buckingham R (ed). Mebendazole. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/05/2019.

Joint Formulary Committee. Mebendazole. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 14/08/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Mebendazole. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 03/07/2014.

Mebendazole Tablet, Chewable (Physicians Total Care, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 03/07/2014.

Primedazol Tablet (Prime Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 07/05/2019.

Vermox Tablet, Chewable (Johnson & Johnson Consumer Inc, Mcneil Consumer Healthcare Division). DailyMed. Source: U.S. National Library of Medicine. Accessed 07/05/2019.

Disclaimer: This information is independently developed by MIMS based on Mebendazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
  • Gavox
  • Vermox 500
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in